HC Wainwright began coverage on shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) in a research note issued to investors on Monday, MarketBeat reports. The firm issued a buy rating and a $9.00 price target on the stock. HC Wainwright also issued estimates for Ovid Therapeutics’ Q1 2024 earnings at ($0.22) EPS, Q2 2024 earnings […]
Related Keywords
China , United States , Jeremym Levin , , Sg Americas Securities , Jump Financial , Ovid Therapeutics Company Profile , Nasdaq , Ovid Therapeutics Inc , China Universal Asset Management Co , Ovid Therapeutics , Free Report , Get Free Report , Universal Asset Management , Financial Markets , Therapeutics Inc , Ovid Therapeutics Daily , Nasdaq Ovid , Covid , Medical , Initiated Coverage , Hc Wainwright ,
vimarsana.com © 2020. All Rights Reserved.